Predictor Role of Systemic Inflammation in Ovarian Cancer
Abstract
Objective: The study aims to investigate the diagnostic value of hemogram derived systemic inflammation parameters in ovarian cancer.
Methods: Totally, the study group consisted of 60 patients with suspected ovarian masses who underwent surgery between February 1th, 2020, and May 1th, 2021, in Ordu University Training and Research Hospital. The patients included in the study were divided into two groups according to postoperative histopathological diagnosis, benign group (consisting of 39 patients) and malign group (consisting of 21 patients). The analysis of the receiver operating characteristic (ROC) curve was used to discover the optimal cut-off values of the hemogram derived blood parameters to predict ovarian cancer.
Results: In the cancer group; 85% of the patients were diagnosed with epithelial ovarian cancer and 62% at late stage. As compares with benign ovarian mass group, the ovarian cancer group had higher neutrophil counts (6.67+3.17 vs 4.64+1.94) (p=0.006), but lower lymphocyte counts (1.60+0.68 vs 2.22+0.64) (p=0.003). The high NLR values (cut-off 2.557) predict ovarian cancer with 71.4% sensitivity and 69.2% specificity (AUC 0.817, p=0.000, CI=0.712-0.922). The high dNLR values (cut- off 1.881) also predict cancer with similar sensitivity and specificity as NLR (AUC 0.814, p=0.000, CI 0.708-0.921). Significant cut-off values for the other hemogram derived parameters were 0.26, 0.0165, 159.66 and 770.611 for MLR, NPR, PLR and SII, respectively. Additionally, the high values of CA 125 (cut-off 34.45) and CA 15-3 (cut-off 16.4) was founded to be related with ovarian cancer.
Conclusions: This paper revealed that high inflammatory parameters such as NLR and dNLR in patients with ovarian masses are mainly associated with ovarian cancer. In the study, it was emphasized that simple and easily accessible hemogram parameters should be used in addition to tumor biomarkers such as CA 125, CA 15-3, which are routinely used in predicting ovarian cancers. We think that more valuable results will be achieved with comprehensive studies designed prospectively.
Keywords
neutrophil-to-lymphocyte ratio , derived neutrophil-to-lymphocyte ratio , systemic inflammation , ovarian cancer
References
- 1. Wild CP, Weiderpass E, Stewart BW, editors. World Cancer Report: International Agency for Research on Cancer. World Health Organization. ISBN (PDF) 978-92-832-0448-0
- 2. Berek JS, Crum C, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2015;131(2):111-22.
- 3. Wang HP, Wu HY, Wang Y, Wang L. Combined detection of tumor markers and serum inflammatory factors in the diagnosis and treatment of gynecologic oncology. J Biol Regul Homeost Agents. 2017;31(3):691-5.
- 4. Liu F, Luo H, Zhu Z, Zhu P, Huang J. Prognostic significance of peripheral blood-derived neutrophil/lymphocyte ratio in patients with digestive cancer. J Cell Physiol. 2019;234(12):22775-86.
- 5. Afzal MZ, Sarwar T, Shirai K. Prognostic Significance of Hematological Indices in Malignant Melanoma Treated With Immune Checkpoint Inhibitors. J Immunother. 2019;42(7):251-64.
- 6. Cho U, Park HS, Im SY, Yoo CY, Jung JH, Suh YJ, et al. Prognostic value of systemic inflammatory markers and development of a nomogram in breast cancer. PLoS One. 2018;26;13(7):e0200936.
- 7. Duan J, Pan L, Yang M. Preoperative elevated neutrophil-to-lymphocyte ratio (NLR) and derived NLR are associated with poor prognosis in patients with breast cancer: A meta-analysis. Medicine (Baltimore). 2018;97(49):e13340. 8. Su S, Liu L, Li C, Zhang J, Li S. Prognostic role of pretreatment derived neutrophil to lymphocyte ratio in urological cancers: A systematic review and meta-analysis. Int J Surg. 2019;72:146-53.
- 9. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;19;140(6):883-99.
- 10. Hagerling C, Casbon AJ, Werb Z. Balancing the innate immune system in tumor development. Trends Cell Biol. 2015;25(4):214-20.
- 11. Lin EY, Pollard JW. Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer. 2004;90(11):2053-8.